By Dr. Ilya Rabkin, MD MBA ·
Reaching your goal weight doesn’t automatically mean it’s time to stop a GLP-1. Weight regain after stopping is common.
Maintenance may be more flexible than staying on the highest dose forever. Newer research suggests some people can preserve much of their weight loss on a lower dose.
GLP-1 medications may continue to help with more than weight, especially blood sugar control and cardiovascular risk in the right patients.
“Microdosing” and spacing injections farther apart are becoming more popular, but we don’t yet know whether very small doses preserve the heart and metabolic benefits seen in major clinical trials.
Muscle deserves attention during major weight loss. Resistance training and adequate protein matter, and creatine may be reasonable for some people, although the GLP-1-specific data are still limited.
After major weight loss, the rest of the medication list may need to change too. Diabetes or blood-pressure treatment that made sense 40 pounds ago may need to be adjusted.
One of the questions I hear after someone has lost a significant amount of weight is whether they really need to keep taking the medication once they’re at goal.
Someone starts semaglutide or tirzepatide, loses 30, 40, sometimes 60 pounds, and gets to a weight they’re happy with. Their blood sugar may be better. Blood pressure may be down. Clothes fit differently. They feel better.
Then things get less straightforward.
Do they stop? Lower the dose? Stretch out the injections? Stay on it for years?
And if weight is no longer the main issue, what are we treating now?
We finally have enough longer-term data that we can answer some of these questions with more than educated guessing.
The studies are pretty consistent.
In the STEP 1 extension, people taking semaglutide had lost an average of 17.3% of their body weight after 68 weeks. One year after treatment stopped, they’d regained about two-thirds of what they had lost. Several improvements in blood pressure, glucose, and other cardiometabolic markers also started drifting back toward baseline.1
Tirzepatide showed a similar pattern. In SURMOUNT-4, participants lost about 20.9% of their weight during the first 36 weeks of treatment. Those who stayed on tirzepatide lost another 5.5% over the following year, while those switched to placebo regained about 14% of their body weight.2
That doesn’t mean everyone who stops will regain everything. Some people do well off treatment.
What it does tell us is that reaching a goal weight doesn’t necessarily erase the biology that contributed to weight gain in the first place.
Hunger can return. The body becomes more efficient after weight loss. Appetite-regulating signals change. Some people also notice the return of persistent thoughts about food — the now-popular term “food noise” — before the scale starts moving very much.
A 2026 survey of 550 adults taking semaglutide found substantial patient-reported reductions in intrusive thoughts about food.3 It’s still an emerging area of research, but it matches what many patients describe in real life.
That’s one reason I think maintenance deserves to be treated as its own phase of care.
A 2026 trial made this question much more interesting.
In SURMOUNT-MAINTAIN, patients completed 60 weeks of tirzepatide at their maximum tolerated dose and were then randomized for another year. Some stayed at the maximum dose, some dropped to 5 mg weekly, and others stopped tirzepatide and received placebo.
At 112 weeks, total weight loss from their original starting weight averaged:
21.9% in the maximum-dose group
16.6% in the 5 mg group
9.9% in the placebo group4
The full dose worked best, but the 5 mg group still preserved considerably more weight loss than the group that stopped.
That’s useful because the discussion around GLP-1s has often been framed as if there are only two choices: stay on the medication indefinitely or come off completely.
The reality may be more individualized.
The 2026 American Diabetes Association Standards now discuss using the lowest effective maintenance dose and recognize that some patients may eventually use intermittent therapy or discontinue treatment with appropriate monitoring.5
We still don’t know who will do best with each strategy, but at least this is now being studied directly.
This is already happening all over the wellness world.
The problem is that “microdosing” doesn’t have one clear meaning. Some people mean staying on the lowest commercially available dose. Others are using very small amounts from compounded medication. Some take a weekly medication every two or three weeks instead.
Those aren’t the same thing, and the evidence behind them isn’t the same either.
We now have randomized evidence supporting dose reduction as a maintenance strategy with tirzepatide.4 Spacing injections farther apart is much less established.
A 2026 retrospective case series followed 30 adults who had reached a weight plateau on semaglutide or tirzepatide and then generally transitioned to every-other-week dosing. On average, their weight and metabolic improvements were maintained for roughly nine months.6
I find that interesting, but it’s still a 30-person retrospective study. I wouldn’t use that alone to tell patients that every-other-week dosing is a proven maintenance strategy.
The same goes for true “microdosing” for inflammation, longevity, or cardiovascular protection. There’s interesting biology behind those ideas, but we don’t know whether tiny doses provide the same benefits seen in the major outcome trials.
This is where the GLP-1 story has expanded well beyond weight loss.
The SELECT trial enrolled more than 17,000 adults with overweight or obesity and established cardiovascular disease who did not have diabetes. Semaglutide reduced the risk of cardiovascular death, heart attack, or stroke by 20% compared with placebo.7
The benefit also doesn’t seem to be explained entirely by weight loss.
A 2026 SELECT analysis looked at high-sensitivity C-reactive protein, or hs-CRP, a commonly used marker of inflammation. Semaglutide lowered hs-CRP by about 38% after two years. The reduction started early, before most of the weight came off, and was also seen in people who lost little or no weight.8
That raises the possibility that part of the cardiovascular benefit comes from effects on inflammation and other pathways that are at least partly separate from weight loss.
This is an area I find especially interesting, but there’s an important limitation: SELECT used therapeutic doses of semaglutide in people who already had cardiovascular disease.
We can’t take those results and assume that a tiny maintenance dose gives a healthy person the same cardiovascular protection. That hasn’t been shown.
I suspect we’re going to learn a lot more about this as researchers get better at separating the effects of weight loss from the other biological effects of these medications.
This can get overlooked after someone has lost a lot of weight.
Think about someone who started with obesity, type 2 diabetes, hypertension, and several medications. Then they lose 40 or 50 pounds.
Their A1c may be much lower. Blood pressure may improve. Insulin requirements may fall. Visceral fat is lower. The overall metabolic picture can look very different from where they started.
At that point, I’d want to review the whole medication list rather than looking only at the GLP-1.
The 2026 ADA guidelines specifically recommend reevaluating insulin and drugs such as sulfonylureas as glucose control improves with GLP-1–based treatment, particularly because of hypoglycemia risk.9
Blood pressure often improves too. A 2026 analysis of 85 randomized trials found that GLP-1 receptor agonists lowered systolic blood pressure by an average of about 3.4 mmHg, with somewhat larger effects from dual and triple incretin medications.10
For some people, that may allow diabetes or blood-pressure medication to be reduced.
I wouldn’t try to eliminate medications just for the sake of having a shorter list, though. An ACE inhibitor or ARB may still be useful because of kidney disease or albumin in the urine. An SGLT2 inhibitor may still matter for kidney or heart-failure protection. A statin can still be indicated after substantial weight loss.9,11
The medication list someone needed before losing weight may not be the right list afterward. It’s worth reassessing each medication based on what it’s actually doing now.
This has become one of the most talked-about concerns around GLP-1 medications.
There’s a real issue behind the headlines, but some of the discussion has become much more dramatic than the data support.
Any time someone loses a substantial amount of weight, some of that loss usually comes from lean tissue. We see that with diet-based weight loss, bariatric surgery, and medications.
In a body-composition substudy of SURMOUNT-1, approximately 75% of the weight lost with tirzepatide was fat and 25% was lean mass.12
One distinction matters here: lean mass on a DXA scan isn’t the same as skeletal muscle. It includes water, organs, connective tissue, and other nonfat tissue.
A 2026 meta-analysis of 20 randomized trials found that lean tissue accounted for roughly 25% to 39% of total weight loss with incretin-based medications, depending on the drug. The proportion was broadly similar to what was seen with intensive lifestyle weight loss, and resistance training was associated with better preservation of lean mass.13
So I don’t think the evidence supports the idea that GLP-1 medications uniquely “eat muscle.”
I do think someone losing a large amount of weight should pay attention to preserving muscle, especially as we get older.
The practical strategy is fairly simple: get enough protein and keep using your muscles.
A 2025 joint advisory from several major obesity, nutrition, and lifestyle-medicine organizations emphasizes both protein intake and resistance training during GLP-1 treatment.14
Protein targets around 1.2–1.6 g/kg/day have been proposed during active weight loss, although calculating that number in someone with obesity gets complicated because there’s no universal agreement about whether to use actual weight, ideal weight, adjusted weight, or lean mass.
For many adults, a more practical target somewhere around 80–120 grams per day may make sense depending on body size, diet, kidney function, activity level, and goals.14
Protein by itself also isn’t enough if the muscles aren’t being challenged. Resistance training gives the body a reason to hold onto muscle.
I’ve written more about protein targets in the ZinovyMed protein guide for anyone who wants to go deeper into that topic.
Creatine is reasonable to consider, especially for people who are already strength training.
It’s one of the better-studied sports supplements. A 2024 meta-analysis found that adding creatine to resistance training resulted in about 1.1 kg more lean mass than resistance training alone in adults younger than 50.15
What we don’t have yet is good evidence showing that creatine specifically prevents lean-mass loss during GLP-1 treatment.
The broader exercise data are strong. The GLP-1-specific data just aren’t there yet.
Once someone reaches a healthier weight, I care about more than whether the scale stays at exactly the same number.
Is the weight reasonably stable? What happened to waist circumference? Blood pressure? A1c and glucose? Lipids? Strength and fitness?
I also want to know whether someone is still eating enough protein and getting adequate nutrition despite having much less appetite. And sometimes the first sign that things are changing isn’t weight at all — it’s hunger returning or food noise creeping back in.
Lifestyle still matters after the medication works. Resistance training, everyday movement, sleep, and a way of eating that someone can actually sustain become especially important in the maintenance phase.
For some people, the medication makes those behaviors easier to maintain. That’s part of why the decision to reduce or stop it isn’t always as simple as reaching a goal weight.
I don’t think every person who successfully loses weight with a GLP-1 needs to stay on the highest dose indefinitely, and I also wouldn’t assume that reaching a goal weight means the medication no longer has a purpose.
Some people may do best staying at their current dose. Some may maintain well at a lower dose. Spacing injections farther apart is interesting, although the evidence is still early. Others may eventually stop medication and maintain their results with lifestyle changes and monitoring.
The decision gets more complicated in someone who also has diabetes, cardiovascular disease, kidney disease, hypertension, or several metabolic problems. In those situations, the medication may be doing much more than controlling appetite.
Once the weight comes off, I’d look at what the medication is doing for that person now, what health risks are still present, and whether the same benefits can be maintained with less medication, the same amount, or eventually none at all.
For many people, losing the weight was the first challenge. Figuring out the right way to maintain those results — and how much medication is actually needed to do it — is becoming the next one.
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725.
Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945.
Arnaut T, Duncan S, Faurby M, et al. Retrospective assessment of food noise changes after initiation of injectable semaglutide for weight management in the USA: the INFORM survey. Adv Ther. 2026;43(8):3649-3659. doi:10.1007/s12325-026-03636-x.
Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026;407(10545):2305-2318. doi:10.1016/S0140-6736(26)00656-2.
American Diabetes Association Professional Practice Committee for Diabetes. Obesity and weight management for the prevention and treatment of diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S008.
Wong M, Wu A, Garhe PK, Biermann M. Reduced-frequency GLP1 therapy maintains weight, body composition, and metabolic syndrome improvements: a case series. Obesity (Silver Spring). 2026;34(Suppl 1):112-120. doi:10.1002/oby.70137.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563.
Plutzky J, Bogdański P, Colhoun HM, et al. Effect of semaglutide on the inflammatory biomarker high-sensitivity CRP in patients with established cardiovascular disease and overweight or obesity in SELECT: a prespecified secondary analysis. Circulation. 2026;154(11):976-991. doi:10.1161/CIRCULATIONAHA.125.074482.
American Diabetes Association Professional Practice Committee for Diabetes. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S009.
Basile C, Merolla A, Mancusi C, et al. Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis. Eur J Prev Cardiol. 2026;33(7):1210-1217. doi:10.1093/eurjpc/zwaf560.
American Diabetes Association Professional Practice Committee for Diabetes. Cardiovascular disease and risk management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S010.
Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. doi:10.1111/dom.16275.
Eisa N, Barood O. Lean mass changes with incretin therapy versus lifestyle intervention: a systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2026;28(6):4818-4827. doi:10.1111/dom.70666.
Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023.
Desai I, Wewege MA, Jones MD, et al. The effect of creatine supplementation on resistance training-based changes to body composition: a systematic review and meta-analysis. J Strength Cond Res. 2024;38(10):1813-1821. doi:10.1519/JSC.0000000000004862.
This article is for educational purposes and does not provide individualized medical advice, diagnosis, or treatment. Decisions about GLP-1–based medications, maintenance dosing, and other medications should be individualized based on medical history, treatment response, other health conditions, and the risks and benefits of continuing, reducing, or stopping therapy.
ZinovyMed provides personalized, physician-led care focused on prevention, longevity, and your long-term health.
Schedule a Consultation